Stock 1530 3SBIO INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company 3SBio Inc.

Equities

1530

KYG8875G1029

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:15 2024-04-18 am EDT 		5-day change 1st Jan Change
5.66 HKD +1.43% Intraday chart for 3SBio Inc. -6.29% -24.73%
Apr. 15 3SBIO Gets China Nod for Use of Cancer Injection in Children with Thrombocytopenia MT
Apr. 12 3SBio Inc. Approves Recombinant Human Thrombopoietin Injection for Pediatric ITP Indication CI

Business Summary

3SBio Inc. is an investment holding company mainly engaged in the the development, production, marketing and sale of pharmaceutical products. The Company’s main products include recombinant human thrombopoietin (rhTPO) products, tumor necrosis factor (TNF)αinhibitor products and recombinant human erythropoietin (rhEPO) products. The products are sold under the name of TPIAO, Yisaipu, EPIAO and SEPO. The Company distributes its products within the domestic market and to overseas markets, including Sri Lanka, Dominican Republic and Thailand. The Company’s subsidiaries include Collected Mind Limited, Hongkong Sansheng Medical Limited and Shenyang Sunshine Pharmaceutical Co., Ltd.. Through its subsidiaries, the Company is engaged in project management and consultation.

Number of employees: 5,411

Sales per Business

HKD in Million2021Weight2022Weight Delta
Biopharmaceutical
100.0 %
7,692 100.0 % 7,977 100.0 % +3.71%

Sales per region

HKD in Million2021Weight2022Weight Delta
China
97.0 %
7,522 97.8 % 7,734 97.0 % +2.82%
Others
3.0 %
170 2.2 % 243 3.0 % +42.76%

Managers

Managers TitleAgeSince
Jing Lou CEO
 Chief Executive Officer 61 92-12-31
Xiang He DFI
 Director of Finance/CFO - 23-07-02
Dong Mei Su BRD
 Director/Board Member 54 12-06-10
Bin Huang BRD
 Director/Board Member 63 92-12-31
Dong Tao Luo PRN
 Corporate Officer/Principal 48 16-02-29
Xin Ma HRO
 Human Resources Officer 58 -
Siu Kuen Lai SEC
 Corporate Secretary 48 14-11-26

Members of the board

Members of the board TitleAgeSince
Bin Huang BRD
 Director/Board Member 63 92-12-31
Jing Lou CEO
 Chief Executive Officer 61 92-12-31
Dong Mei Su BRD
 Director/Board Member 54 12-06-10
Tian Ruo Pu BRD
 Director/Board Member 55 15-05-31
Joo Yeow Ng BRD
 Director/Board Member 59 22-01-20
Hoi Ti Yang BRD
 Director/Board Member 54 21-06-28
Dan Zhang BRD
 Director/Board Member 60 22-12-29

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 2,438,920,412 1,803,786,336 ( 73.96 %) 40,357,688 ( 1.655 %) 73.96 %

Shareholders

NameEquities%Valuation
Jing Lou
21.61 %
527,000,616 21.61 % 403 M $
CITIC Private Equity Funds Management Co Ltd
2.000 %
48,776,909 2.000 % 37 M $
Bin Huang
1.320 %
32,197,350 1.320 % 25 M $
Bankinter Gestión de Activos SA SGIIC
1.088 %
26,524,000 1.088 % 20 M $
Dong Mei Su
0.9998 %
24,384,630 0.9998 % 19 M $
BlackRock Fund Advisors
0.7719 %
18,825,000 0.7719 % 14 M $
Bosera Asset Management Co., Ltd.
0.5457 %
13,309,500 0.5457 % 10 M $
BlackRock (Netherlands) BV
0.4656 %
11,354,636 0.4656 % 9 M $
BlackRock Investment Management (UK) Ltd.
0.4191 %
10,221,831 0.4191 % 8 M $
State Street Global Advisors Ltd.
0.2172 %
5,298,491 0.2172 % 4 M $

Holdings

NameEquities%Valuation
SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD
95.20%
 498,883,645 95.20% 1,578,632,484 $
SENSORION
1.47%
 4,055,150 1.47% 3,367,883 $

Company contact information

3SBio, Inc.

Shenyang Economy & Tech Development No. 3 A1, Road 10

110027, Shenyang

+86 24 2538 6000

http://www.3sbio.com
address 3SBio Inc.(1530)

Group companies

NameCategory and Sector
Hongkong Sansheng Medical Ltd.
Logo Hongkong Sansheng Medical Ltd.

Hongkong Sansheng Medical Ltd.

Pharmaceuticals: MajorHealth Technology

Hongkong Sansheng Medical Ltd. develops and commercializes oral disintegration tablet formulation of antipruritic drug. The company is headquartered is Hong Kong.

Pharmaceuticals: Major

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per region

Ratings for 3SBio Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
5.158 CNY
Average target price
6.887 CNY
Spread / Average Target
+33.51%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
3SBIO INC. Stock 3SBio Inc.
-24.60% 1.7B
CSL LIMITED Stock CSL Limited
-5.32% 84.57B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.11% 39.93B
BIOGEN INC. Stock Biogen Inc.
-25.74% 27.93B
UCB Stock UCB
+52.85% 24.21B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-6.17% 17.17B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-31.09% 13.93B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-6.58% 12.3B
INCYTE CORPORATION Stock Incyte Corporation
-16.04% 11.84B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
-3.60% 7.91B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 1530 Stock
  4. Company 3SBio Inc.